Trial Profile
Reversal of residual pipecuronium neuromuscular block using sugammadex: a randomized, double-blind, placebo controlled, dosefinding study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Oct 2015
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- 28 Oct 2015 New trial record